Treace Medical Concepts (TMCI) EBITDA (2020 - 2026)

Treace Medical Concepts has reported EBITDA for 7 years, with the latest figure at -$18.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 13.14% year-over-year to -$18.1 million; the trailing twelve-month figure through Mar 2026 stood at -$61.1 million (down 15.33% YoY), and the FY2025 full-year result was -$59.0 million, down 5.77% from the prior year.
• EBITDA for Q1 2026 stood at -$18.1 million, down from -$9.4 million in the prior quarter.
• The five-year high for EBITDA was -$595000.0 in Q4 2024, with the low at -$21.3 million in Q2 2024.
• Historically, EBITDA has averaged -$13.2 million across 5 years, with a median of -$15.1 million in 2024.
• Annual changes were most pronounced in 2024 — EBITDA soared 90.03% — and 2025, when it plunged 1480.67%.
• Treace Medical Concepts' EBITDA stood at -$4.4 million in 2022, then plunged by 34.49% to -$6.0 million in 2023, then soared by 90.03% to -$595000.0 in 2024, then sank by 1480.67% to -$9.4 million in 2025, then slumped by 92.01% to -$18.1 million in 2026.
• The last three EBITDA figures came in at -$18.1 million (Q1 2026), -$9.4 million (Q4 2025), and -$16.3 million (Q3 2025), per Business Quant data.